Since the launch of the anti-anxiety drug Sediel^® in China, the company has been actively promoting the development of therapeutics for central nervous system disorders with a patient-centered approach for more than a decade to benefit more patients. In the meantime, the company has been comprehensively exploring the central nervous system field and continuously enriching its product line. In 2018 and 2019, the new anti-schizophrenic drugs Lonasen^® (blonanserin tablets) and Latuda^®(lurasidone hydrochloride tablets) were launched, which broke the dilemma that no new compound has been marketed in the field of schizophrenia in China for nearly ten years.